Fingerprint
Dive into the research topics of 'Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically